JP2019507580A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507580A5
JP2019507580A5 JP2018522707A JP2018522707A JP2019507580A5 JP 2019507580 A5 JP2019507580 A5 JP 2019507580A5 JP 2018522707 A JP2018522707 A JP 2018522707A JP 2018522707 A JP2018522707 A JP 2018522707A JP 2019507580 A5 JP2019507580 A5 JP 2019507580A5
Authority
JP
Japan
Prior art keywords
antibody
seq
optionally
cdr
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522707A
Other languages
English (en)
Japanese (ja)
Other versions
JP7065516B2 (ja
JP2019507580A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2016/051300 external-priority patent/WO2017079831A1/en
Publication of JP2019507580A publication Critical patent/JP2019507580A/ja
Publication of JP2019507580A5 publication Critical patent/JP2019507580A5/ja
Application granted granted Critical
Publication of JP7065516B2 publication Critical patent/JP7065516B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522707A 2015-11-09 2016-11-09 アミロイドベータのn末端エピトープおよびそれに対する立体配座選択的抗体 Active JP7065516B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562253044P 2015-11-09 2015-11-09
US62/253,044 2015-11-09
US201662331925P 2016-05-04 2016-05-04
US62/331,925 2016-05-04
US201662365634P 2016-07-22 2016-07-22
US62/365,634 2016-07-22
US201662393615P 2016-09-12 2016-09-12
US62/393,615 2016-09-12
PCT/CA2016/051300 WO2017079831A1 (en) 2015-11-09 2016-11-09 N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto

Publications (3)

Publication Number Publication Date
JP2019507580A JP2019507580A (ja) 2019-03-22
JP2019507580A5 true JP2019507580A5 (https=) 2019-12-19
JP7065516B2 JP7065516B2 (ja) 2022-05-12

Family

ID=58694490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018522707A Active JP7065516B2 (ja) 2015-11-09 2016-11-09 アミロイドベータのn末端エピトープおよびそれに対する立体配座選択的抗体

Country Status (9)

Country Link
US (2) US10772969B2 (https=)
EP (1) EP3374379A4 (https=)
JP (1) JP7065516B2 (https=)
KR (1) KR102776187B1 (https=)
CN (1) CN108350051A (https=)
AU (2) AU2016353552B2 (https=)
CA (1) CA3004482A1 (https=)
HK (1) HK1259325A1 (https=)
WO (1) WO2017079831A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
JP6952351B2 (ja) 2015-11-09 2021-10-20 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 集団座標バイアシングによりミスフォールディングタンパク質エピトープを予測するためのシステムおよび方法
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
KR102523019B1 (ko) * 2018-05-30 2023-04-18 내셔날 헬스 리서치 인스티튜트 항-a베타 항체 및 이의 용도
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN110010206B (zh) * 2019-03-28 2022-03-29 华南理工大学 一种蛋白在二氧化钛表面上吸附行为的仿真调控方法
CA3167073A1 (en) * 2020-03-10 2021-09-16 Preeti BAKRANIA Cyclic peptides
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
GB8911525D0 (en) 1989-05-19 1989-07-05 Allied Colloids Ltd Polymeric composition
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1995006477A1 (en) 1993-08-31 1995-03-09 Gliatech, Inc. Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US6043283A (en) 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7012061B1 (en) 1998-10-19 2006-03-14 New York University Method for increasing the permeability of the blood brain barrier
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
CA2538076A1 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
CN1562050A (zh) 2004-03-24 2005-01-12 中国海洋大学 褐藻酸寡糖在抗痴呆、抗糖尿病中的应用
US20050267029A1 (en) 2004-04-02 2005-12-01 Ancsin John B Compounds which modulate amyloidogenesis and methods for their identification and use
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
EP1893576A4 (en) 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments
UA99097C2 (ru) 2005-12-12 2012-07-25 Ф. Хоффманн-Ля Рош Аг Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
KR20150002879A (ko) 2006-10-02 2015-01-07 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US20100081613A1 (en) * 2006-10-11 2010-04-01 The Trustees Of Columbia University In The City Of New York Methods and compositions for enhancing memory
PT2121754E (pt) 2007-01-18 2015-05-11 Lilly Co Eli Fab de beta-amilóide peguilado
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2170389T3 (pl) 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
CA2701788C (en) 2007-10-05 2017-06-13 Genentech, Inc. Humanized beta-amyloid antibody for treating ocular diseases
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
US20090246191A1 (en) 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2207568T3 (en) * 2007-11-16 2017-09-18 Univ Rockefeller ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
RU2011100127A (ru) 2008-06-12 2012-07-20 Аффирис Аг (At) Соединение, содержащее пептид, для лечения симптомов болезни паркинсона
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
AU2009301580B2 (en) 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102459335B (zh) 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
WO2010128139A1 (en) 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
EP2478365A1 (en) 2009-09-18 2012-07-25 Probiodrug AG Novel assay for the detection of amyloid beta peptides
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
RU2644335C2 (ru) * 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
WO2012051498A2 (en) 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN104093454A (zh) * 2011-11-10 2014-10-08 坎格尼美国股份有限公司 治疗阿耳茨海默氏病的组合物和方法
CA2885924C (en) 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
WO2015017900A1 (en) 2013-08-05 2015-02-12 St. Vincent's Institute Of Medical Research An antibody therapy for amyloid beta disease
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
US20170021020A1 (en) 2015-07-23 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal antibody and vaccine targeting filamentous bacteriophage
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
JP6952351B2 (ja) 2015-11-09 2021-10-20 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 集団座標バイアシングによりミスフォールディングタンパク質エピトープを予測するためのシステムおよび方法
EP3374380A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia C-terminal epitopes in amyloid-beta and conformation-sensitive antibodies
CA3004496A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide

Similar Documents

Publication Publication Date Title
JP2019507580A5 (https=)
JP2019505166A5 (https=)
US20210024635A1 (en) Anti-wt1/hla-specific antibodies
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
JP2019504615A5 (https=)
AU2011252851B2 (en) Humanized and chimeric monoclonal antibodies to CD47
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
JP7722990B2 (ja) アミロイド沈着物を標的化するための修飾免疫グロブリン
JP7212391B2 (ja) a-syn/IGF1Rに対する二重特異抗体およびその用途
NZ717476A (en) Anti-garp protein and uses thereof
AU2015357533A1 (en) Antibodies targeting B-cell maturation antigen and methods of use
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
CN116745317B (zh) 抗tigit抗体及其用途
JP7672172B2 (ja) 抗SIRPαモノクローナル抗体およびその使用
JP2020515277A5 (https=)
CA3183471A1 (en) Anti-b7h4 antibody, and bispecific antibody and use thereof
CN109721656B (zh) 靶向rankl的治疗性抗体
JP2020522475A5 (https=)
JP2022500455A5 (https=)
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CA3219659A1 (en) Antibodies for treating alpha-synucleinopathies
WO2025086564A1 (zh) 抗人vsig4的抗体及其医药用途
AU2015336946A1 (en) Fn14-binding proteins and uses thereof
HK40100726A (zh) 抗tigit抗体及其用途
EA048681B1 (ru) Модифицированные иммуноглобулины для нацеливания на амилоидные отложения